solelyrelatedtothestudy,presumablyatthephysician'sdiscretion.Additionally,theauthorpostulatedthatthiscostseparation is necessary since sponsors, rather than institutions, should cover sponsor-related costs; presently some of these costsarebornebyphysiciansandmedicalcenters.
The author also proffers the use of marginal cost estimationofservicesascalculatedbasedonaveragingflatratesto assistindeterminingcostallocation.Jacobsnextrecommends a series of steps designed to further delineate costs prior to pursuingacontractualrelationshipwithastudysponsor.For thesesteps,Jacobsproposestheevaluationofthestudycontracttodeterminedepthofreimbursementandallocationof off-labelmedications.Hismodelurgesphysicianstomakea concerted effort to renegotiate contracts that fail the above coststestsandwherenegotiationsfail,toredirecttheseefforts towards study protocol revisions that are in line with existingcoststructuresatthemedicalinstitution.Institutionsand physicians are also encouraged to underwrite observational study costs or refer patients to community institutions with bettercoststructuresandcomparablecancertherapies.
Therearesomepracticalquestionsthatariseininterpretingthesefindingsandrecommendations.Whatistheclinical impactofdemonstratingseparatedcostsinthecontextofclinicaltrials?Fortrialsthathavethepotentialtoprolongsurvivalandimprovequalityoflife,costsnegotiationscouldinsert negative outcomes into the equation. Furthermore, clinical trialcostsmayalsobeaffectedbyfactorsthatarenotmediatedthroughthetrialandbymechanismsthatareindependent ofthetrialprocess.Someofthesefactorsincludeunexpected opportunitycostsandcostsrelatedtoadversedrugreactions orevents.Regulatorymandatesandsubjectresponsetotherapiesmightalsoleadtoprolongationoftrialsandincreasein costs.
Inourpriorpilotstudythatinvestigatedclinicaltrialcosts we also found that detailed economic information was critiSpecialchallengesarefrequentlyencounteredwhentryingto increasepatientrecruitmentintoclinicaltrials.Inclinicaltrials,itisnecessarythatlargenumbersofpatientsarerecruited toallowforsubjectstratificationforlargevariables,thereby contributinggreatlytoslowprogressinreachingrecruitment targets.Whileclinicaltrialsarecriticaltoimprovingpatient outcomes in all areas, including cancer, strategy modifications are essential to balance recruitment efforts against trial costs. The allocation of scarce health care resources is increasinglybaseduponeconomicevaluationsofhealthcare interventions. Since clinical trials have the potential to dissipatemanyoftheseresourcestheymustbeconductedwith costsinmind.
In the current issue of OnkOlOgie, Jacobs reports on the pressuresfacedbyclinicianstoincreasepatientparticipation inclinicaltrialsandtheattendantfinancialimpactonmedical institutionsthatchoosetodoso [1] .Concernedaboutthedifficultiesinherentinseparatingmedicalcarefrom'studycare' for patients enrolled in clinical trials, the author postulates that clinical trial costs should be reimbursed in concert with standard of care cancer costs. He utilizes a decision-making algorithmicprocesstodetermineparticipationinclinicaltrials basedoneconomicandbudgetimpacts.Theeconomicmodel presentedwasderivedfrombothprospectiveandretrospective studies evaluating the procedures and costs associated withclinicaltrialprotocolsforbreastandovariancancer.Proceduresandcostestimateswereobtainedfromconsultations withacenterthatmanagesclinicaltrialsandwithseveralhospitaldepartments.
Jacobsfoundthat,tocontrolforclinicaltrialcosts,anetworkofproviderswithexpertiseineconomicsisneeded;costs shouldbesummedfromindividualcostsofeachserviceprovidedbasedonadetailedresearchprotocol.Theauthoralso foundthatcostsmustbeseparatedbythosethataredirected towards medically-related interventions and those that are Onkologie2009;32:378-379
Cost-EffectiveClinicalTrials 379 cal to the analyses [2] . Our study of 70 cancer patients enrolledinphaseIIclinicaltrialsfoundthat,in1996,chargesfor participants on cancer-related clinical trials were no greater than charges for participants incurred outside of the clinical trialsetting.Theseestimateswerecomparablewiththosereported from other single-site studies [3, 4] . Furthermore, in theirstudymeasuringthecost-effectivenessofsevenselected randomizedtrials,Detskyetal.foundthesetrialstobegood investments,withlowerdollarperlife-yearsavedratiosthan thoseassociatedwiththeproveninterventions [5] . AnotherstudybyChirikosetal.supportsthefindingsfrom priorstudiesthatrevealednosignificantincreaseintreatment costs for cancer patients enrolled in clinical trials [6] . The study,however,hadnotablelimitations:itexcludedphysician fees,lookingonlyatin-patientandout-patienthospitalcare; it used data on charges from hospital billing records, which donotcomportwellwithactualpaymentsandunderlyingresourcecosts;costswereadjustedforthetypeandcomplexity oftheinitialtherapy,potentiallyunderestimatingtrialassociatedcosts [6] .Unquestionably,overallcostsforclinicaltrials haveincreasedwithtimeandmanyofthesestudiesshouldbe revisitedtoreassessthefindings.
Themodelproposedinthisarticle,thoughtransparentand seeminglystraight-forward,shouldberevised orrevisitedto takeintoaccountothercostcriteriaofrelevance.Untilthen, thismodelshouldbeutilizedagainstthebackdropofthelimitationsmentionedpreviously.
